Accuray Incorporated

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ARAY is priced at $0.38, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ARAY's ROE is -0.77%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ARAY is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check BSX-PA's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ISRG has a market cap of 155.2B. Regarding current trading prices, ARAY is priced at $0.38, while ISRG trades at $439.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ISRG's P/E ratio is 53.17. In terms of profitability, ARAY's ROE is -0.77%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, ARAY is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ISRG's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ABT has a market cap of 152.3B. Regarding current trading prices, ARAY is priced at $0.38, while ABT trades at $86.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ABT's P/E ratio is 24.48. In terms of profitability, ARAY's ROE is -0.77%, compared to ABT's ROE of +0.12%. Regarding short-term risk, ARAY is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ABT's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SYK has a market cap of 121.3B. Regarding current trading prices, ARAY is priced at $0.38, while SYK trades at $311.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SYK's P/E ratio is 36.63. In terms of profitability, ARAY's ROE is -0.77%, compared to SYK's ROE of +0.15%. Regarding short-term risk, ARAY is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SYK's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, MDT has a market cap of 100.9B. Regarding current trading prices, ARAY is priced at $0.38, while MDT trades at $77.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas MDT's P/E ratio is 21.96. In terms of profitability, ARAY's ROE is -0.77%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ARAY is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check MDT's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BSX has a market cap of 85.9B. Regarding current trading prices, ARAY is priced at $0.38, while BSX trades at $57.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BSX's P/E ratio is 24.18. In terms of profitability, ARAY's ROE is -0.77%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ARAY is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check BSX's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BRKRP has a market cap of 53.1B. Regarding current trading prices, ARAY is priced at $0.38, while BRKRP trades at $324.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BRKRP's P/E ratio is N/A. In terms of profitability, ARAY's ROE is -0.77%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, ARAY is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check BRKRP's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, EW has a market cap of 49.4B. Regarding current trading prices, ARAY is priced at $0.38, while EW trades at $86.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas EW's P/E ratio is 46.37. In terms of profitability, ARAY's ROE is -0.77%, compared to EW's ROE of +0.11%. Regarding short-term risk, ARAY is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check EW's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, RMD has a market cap of 30.2B. Regarding current trading prices, ARAY is priced at $0.38, while RMD trades at $207.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas RMD's P/E ratio is 20.08. In terms of profitability, ARAY's ROE is -0.77%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ARAY is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check RMD's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, DXCM has a market cap of 27.8B. Regarding current trading prices, ARAY is priced at $0.38, while DXCM trades at $71.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas DXCM's P/E ratio is 30.94. In terms of profitability, ARAY's ROE is -0.77%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, ARAY is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check DXCM's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, PHG has a market cap of 25.7B. Regarding current trading prices, ARAY is priced at $0.38, while PHG trades at $26.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas PHG's P/E ratio is 23.23. In terms of profitability, ARAY's ROE is -0.77%, compared to PHG's ROE of +0.09%. Regarding short-term risk, ARAY is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check PHG's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, STE has a market cap of 21.3B. Regarding current trading prices, ARAY is priced at $0.38, while STE trades at $214.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas STE's P/E ratio is 27.31. In terms of profitability, ARAY's ROE is -0.77%, compared to STE's ROE of +0.11%. Regarding short-term risk, ARAY is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check STE's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ARAY is priced at $0.38, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ARAY's ROE is -0.77%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ARAY is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ABMD's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ZBH has a market cap of 16.5B. Regarding current trading prices, ARAY is priced at $0.38, while ZBH trades at $85.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ZBH's P/E ratio is 22.15. In terms of profitability, ARAY's ROE is -0.77%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ARAY is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ZBH's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SNN has a market cap of 13B. Regarding current trading prices, ARAY is priced at $0.38, while SNN trades at $30.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SNN's P/E ratio is 21.35. In terms of profitability, ARAY's ROE is -0.77%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ARAY is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SNN's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, ARAY is priced at $0.38, while PEN trades at $328.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas PEN's P/E ratio is 75.74. In terms of profitability, ARAY's ROE is -0.77%, compared to PEN's ROE of +0.12%. Regarding short-term risk, ARAY is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check PEN's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ARAY is priced at $0.38, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ARAY's ROE is -0.77%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ARAY is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SWAV's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ALGN has a market cap of 11.7B. Regarding current trading prices, ARAY is priced at $0.38, while ALGN trades at $164.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ALGN's P/E ratio is 27.45. In terms of profitability, ARAY's ROE is -0.77%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ARAY is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ALGN's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, GMED has a market cap of 11.4B. Regarding current trading prices, ARAY is priced at $0.38, while GMED trades at $85.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas GMED's P/E ratio is 19.82. In terms of profitability, ARAY's ROE is -0.77%, compared to GMED's ROE of +0.13%. Regarding short-term risk, ARAY is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check GMED's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, PODD has a market cap of 10.7B. Regarding current trading prices, ARAY is priced at $0.38, while PODD trades at $154.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas PODD's P/E ratio is 36.27. In terms of profitability, ARAY's ROE is -0.77%, compared to PODD's ROE of +0.21%. Regarding short-term risk, ARAY is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check PODD's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ARAY is priced at $0.38, while MASI trades at $178.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas MASI's P/E ratio is 44.26. In terms of profitability, ARAY's ROE is -0.77%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ARAY is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check MASI's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BIO has a market cap of 7.8B. Regarding current trading prices, ARAY is priced at $0.38, while BIO trades at $287.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BIO's P/E ratio is 47.88. In terms of profitability, ARAY's ROE is -0.77%, compared to BIO's ROE of +0.02%. Regarding short-term risk, ARAY is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check BIO's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BIO-B has a market cap of 7.5B. Regarding current trading prices, ARAY is priced at $0.38, while BIO-B trades at $276.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BIO-B's P/E ratio is 46.10. In terms of profitability, ARAY's ROE is -0.77%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, ARAY is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check BIO-B's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, ARAY is priced at $0.38, while GKOS trades at $116.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas GKOS's P/E ratio is -36.54. In terms of profitability, ARAY's ROE is -0.77%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, ARAY is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check GKOS's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BRKR has a market cap of 7B. Regarding current trading prices, ARAY is priced at $0.38, while BRKR trades at $46.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BRKR's P/E ratio is -190.37. In terms of profitability, ARAY's ROE is -0.77%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, ARAY is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check BRKR's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ARAY is priced at $0.38, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas NARI's P/E ratio is -59.24. In terms of profitability, ARAY's ROE is -0.77%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ARAY is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check NARI's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, LIVN has a market cap of 4.1B. Regarding current trading prices, ARAY is priced at $0.38, while LIVN trades at $74.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas LIVN's P/E ratio is 37.67. In terms of profitability, ARAY's ROE is -0.77%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, ARAY is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check LIVN's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, ARAY is priced at $0.38, while IRTC trades at $115.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas IRTC's P/E ratio is -137.13. In terms of profitability, ARAY's ROE is -0.77%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, ARAY is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check IRTC's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ARAY is priced at $0.38, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ARAY's ROE is -0.77%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ARAY is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check AXNX's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, ARAY is priced at $0.38, while ITGR trades at $89.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ITGR's P/E ratio is 22.15. In terms of profitability, ARAY's ROE is -0.77%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, ARAY is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ITGR's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, ARAY is priced at $0.38, while TMDX trades at $70.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas TMDX's P/E ratio is 15.77. In terms of profitability, ARAY's ROE is -0.77%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, ARAY is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check TMDX's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, ARAY is priced at $0.38, while AXGN trades at $41.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas AXGN's P/E ratio is -63.91. In terms of profitability, ARAY's ROE is -0.77%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, ARAY is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check AXGN's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, ARAY is priced at $0.38, while ESTA trades at $73.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ESTA's P/E ratio is -49.11. In terms of profitability, ARAY's ROE is -0.77%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, ARAY is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ESTA's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ARAY is priced at $0.38, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ARAY's ROE is -0.77%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ARAY is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check NUVA's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, ARAY is priced at $0.38, while UFPT trades at $222.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas UFPT's P/E ratio is 26.11. In terms of profitability, ARAY's ROE is -0.77%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ARAY is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check UFPT's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, PRCT has a market cap of 1.7B. Regarding current trading prices, ARAY is priced at $0.38, while PRCT trades at $28.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas PRCT's P/E ratio is -15.85. In terms of profitability, ARAY's ROE is -0.77%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ARAY is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check PRCT's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, ARAY is priced at $0.38, while AHCO trades at $10.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas AHCO's P/E ratio is -17.71. In terms of profitability, ARAY's ROE is -0.77%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, ARAY is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check AHCO's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, ARAY is priced at $0.38, while ENOV trades at $24.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ENOV's P/E ratio is -1.22. In terms of profitability, ARAY's ROE is -0.77%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, ARAY is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ENOV's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ARAY is priced at $0.38, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ARAY's ROE is -0.77%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ARAY is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check HSKA's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, ARAY is priced at $0.38, while ATEC trades at $8.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ATEC's P/E ratio is -9.96. In terms of profitability, ARAY's ROE is -0.77%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, ARAY is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ATEC's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, ARAY is priced at $0.38, while INSP trades at $42.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas INSP's P/E ratio is 9.96. In terms of profitability, ARAY's ROE is -0.77%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ARAY is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check INSP's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ARAY is priced at $0.38, while IRMD trades at $92.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas IRMD's P/E ratio is 50.33. In terms of profitability, ARAY's ROE is -0.77%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, ARAY is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check IRMD's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, ARAY is priced at $0.38, while IART trades at $15.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas IART's P/E ratio is -2.33. In terms of profitability, ARAY's ROE is -0.77%, compared to IART's ROE of -0.48%. Regarding short-term risk, ARAY is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check IART's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, ARAY is priced at $0.38, while BFLY trades at $4.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BFLY's P/E ratio is -14.90. In terms of profitability, ARAY's ROE is -0.77%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, ARAY is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check BFLY's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ARAY is priced at $0.38, while AVNS trades at $24.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas AVNS's P/E ratio is -15.38. In terms of profitability, ARAY's ROE is -0.77%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ARAY is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check AVNS's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, ARAY is priced at $0.38, while CNMD trades at $36.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas CNMD's P/E ratio is 21.03. In terms of profitability, ARAY's ROE is -0.77%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, ARAY is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check CNMD's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ARAY is priced at $0.38, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SILK's P/E ratio is -18.96. In terms of profitability, ARAY's ROE is -0.77%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ARAY is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SILK's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ARAY is priced at $0.38, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas FNA's P/E ratio is -19.83. In terms of profitability, ARAY's ROE is -0.77%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ARAY is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check FNA's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, ARAY is priced at $0.38, while AORT trades at $22.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas AORT's P/E ratio is 89.84. In terms of profitability, ARAY's ROE is -0.77%, compared to AORT's ROE of +0.03%. Regarding short-term risk, ARAY is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check AORT's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, ARAY is priced at $0.38, while TNDM trades at $15.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas TNDM's P/E ratio is -10.92. In terms of profitability, ARAY's ROE is -0.77%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, ARAY is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check TNDM's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, INMD has a market cap of 870.5M. Regarding current trading prices, ARAY is priced at $0.38, while INMD trades at $13.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas INMD's P/E ratio is 10.18. In terms of profitability, ARAY's ROE is -0.77%, compared to INMD's ROE of +0.13%. Regarding short-term risk, ARAY is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check INMD's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ARAY is priced at $0.38, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas CSII's P/E ratio is -20.83. In terms of profitability, ARAY's ROE is -0.77%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ARAY is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check CSII's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SSII has a market cap of 778.5M. Regarding current trading prices, ARAY is priced at $0.38, while SSII trades at $3.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SSII's P/E ratio is -77.80. In terms of profitability, ARAY's ROE is -0.77%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ARAY is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SSII's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, LMRI has a market cap of 768.6M. Regarding current trading prices, ARAY is priced at $0.38, while LMRI trades at $8.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas LMRI's P/E ratio is -20.51. In terms of profitability, ARAY's ROE is -0.77%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, ARAY is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check LMRI's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ARAY is priced at $0.38, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas CRY's P/E ratio is 425.71. In terms of profitability, ARAY's ROE is -0.77%, compared to CRY's ROE of +0.03%. Regarding short-term risk, ARAY is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check CRY's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, CBLL has a market cap of 712.2M. Regarding current trading prices, ARAY is priced at $0.38, while CBLL trades at $18.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas CBLL's P/E ratio is -11.59. In terms of profitability, ARAY's ROE is -0.77%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, ARAY is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check CBLL's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SIBN has a market cap of 651M. Regarding current trading prices, ARAY is priced at $0.38, while SIBN trades at $14.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SIBN's P/E ratio is -37.64. In terms of profitability, ARAY's ROE is -0.77%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, ARAY is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SIBN's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BVS has a market cap of 628.7M. Regarding current trading prices, ARAY is priced at $0.38, while BVS trades at $9.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BVS's P/E ratio is 22.63. In terms of profitability, ARAY's ROE is -0.77%, compared to BVS's ROE of +0.16%. Regarding short-term risk, ARAY is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check BVS's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ARAY is priced at $0.38, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ARAY's ROE is -0.77%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, ARAY is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SRDX's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BWAY has a market cap of 592.3M. Regarding current trading prices, ARAY is priced at $0.38, while BWAY trades at $16.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BWAY's P/E ratio is 68.64. In terms of profitability, ARAY's ROE is -0.77%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ARAY is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check BWAY's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ARAY is priced at $0.38, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas APEN's P/E ratio is -9.43. In terms of profitability, ARAY's ROE is -0.77%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ARAY is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check APEN's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, NPCE has a market cap of 576.9M. Regarding current trading prices, ARAY is priced at $0.38, while NPCE trades at $16.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas NPCE's P/E ratio is -26.03. In terms of profitability, ARAY's ROE is -0.77%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ARAY is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check NPCE's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, TCMD has a market cap of 561.7M. Regarding current trading prices, ARAY is priced at $0.38, while TCMD trades at $24.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas TCMD's P/E ratio is 28.62. In terms of profitability, ARAY's ROE is -0.77%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, ARAY is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check TCMD's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, CERS has a market cap of 543M. Regarding current trading prices, ARAY is priced at $0.38, while CERS trades at $2.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas CERS's P/E ratio is -54.20. In terms of profitability, ARAY's ROE is -0.77%, compared to CERS's ROE of -0.15%. Regarding short-term risk, ARAY is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check CERS's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ARAY is priced at $0.38, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ARAY's ROE is -0.77%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, ARAY is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ZIMV's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, CTKB has a market cap of 517.9M. Regarding current trading prices, ARAY is priced at $0.38, while CTKB trades at $3.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas CTKB's P/E ratio is -6.91. In terms of profitability, ARAY's ROE is -0.77%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, ARAY is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check CTKB's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, KIDS has a market cap of 471.8M. Regarding current trading prices, ARAY is priced at $0.38, while KIDS trades at $18.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas KIDS's P/E ratio is -10.93. In terms of profitability, ARAY's ROE is -0.77%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ARAY is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check KIDS's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, OFIX has a market cap of 434.5M. Regarding current trading prices, ARAY is priced at $0.38, while OFIX trades at $10.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas OFIX's P/E ratio is -7.17. In terms of profitability, ARAY's ROE is -0.77%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, ARAY is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check OFIX's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, VREX has a market cap of 423.9M. Regarding current trading prices, ARAY is priced at $0.38, while VREX trades at $10.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas VREX's P/E ratio is -5.03. In terms of profitability, ARAY's ROE is -0.77%, compared to VREX's ROE of -0.18%. Regarding short-term risk, ARAY is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check VREX's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, LAB has a market cap of 402.1M. Regarding current trading prices, ARAY is priced at $0.38, while LAB trades at $1.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas LAB's P/E ratio is -7.92. In terms of profitability, ARAY's ROE is -0.77%, compared to LAB's ROE of -0.21%. Regarding short-term risk, ARAY is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check LAB's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, DCTH has a market cap of 380.4M. Regarding current trading prices, ARAY is priced at $0.38, while DCTH trades at $11.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas DCTH's P/E ratio is 1102.00. In terms of profitability, ARAY's ROE is -0.77%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, ARAY is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check DCTH's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, PACB has a market cap of 378.9M. Regarding current trading prices, ARAY is priced at $0.38, while PACB trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas PACB's P/E ratio is -2.98. In terms of profitability, ARAY's ROE is -0.77%, compared to PACB's ROE of -4.88%. Regarding short-term risk, ARAY is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check PACB's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, VMD has a market cap of 370M. Regarding current trading prices, ARAY is priced at $0.38, while VMD trades at $9.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas VMD's P/E ratio is 26.08. In terms of profitability, ARAY's ROE is -0.77%, compared to VMD's ROE of +0.11%. Regarding short-term risk, ARAY is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check VMD's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, AVR has a market cap of 353.9M. Regarding current trading prices, ARAY is priced at $0.38, while AVR trades at $9.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas AVR's P/E ratio is -4.33. In terms of profitability, ARAY's ROE is -0.77%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ARAY is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check AVR's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, CLPT has a market cap of 343.1M. Regarding current trading prices, ARAY is priced at $0.38, while CLPT trades at $12.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas CLPT's P/E ratio is -11.44. In terms of profitability, ARAY's ROE is -0.77%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, ARAY is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check CLPT's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ELMD has a market cap of 316.5M. Regarding current trading prices, ARAY is priced at $0.38, while ELMD trades at $37.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ELMD's P/E ratio is 32.67. In terms of profitability, ARAY's ROE is -0.77%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ARAY is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ELMD's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ARAY is priced at $0.38, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ARAY's ROE is -0.77%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, ARAY is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SMLR's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, CATX has a market cap of 307.5M. Regarding current trading prices, ARAY is priced at $0.38, while CATX trades at $3.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas CATX's P/E ratio is -2.82. In terms of profitability, ARAY's ROE is -0.77%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ARAY is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check CATX's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, MASS has a market cap of 275.3M. Regarding current trading prices, ARAY is priced at $0.38, while MASS trades at $7.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas MASS's P/E ratio is -7.51. In terms of profitability, ARAY's ROE is -0.77%, compared to MASS's ROE of -0.26%. Regarding short-term risk, ARAY is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check MASS's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SGHT has a market cap of 273.7M. Regarding current trading prices, ARAY is priced at $0.38, while SGHT trades at $4.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SGHT's P/E ratio is -7.19. In terms of profitability, ARAY's ROE is -0.77%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, ARAY is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SGHT's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SENS has a market cap of 265M. Regarding current trading prices, ARAY is priced at $0.38, while SENS trades at $6.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SENS's P/E ratio is -3.22. In terms of profitability, ARAY's ROE is -0.77%, compared to SENS's ROE of -1.30%. Regarding short-term risk, ARAY is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SENS's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, RXST has a market cap of 251.9M. Regarding current trading prices, ARAY is priced at $0.38, while RXST trades at $6.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas RXST's P/E ratio is -5.38. In terms of profitability, ARAY's ROE is -0.77%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ARAY is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check RXST's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ARAY is priced at $0.38, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas MGRM's P/E ratio is -11.11. In terms of profitability, ARAY's ROE is -0.77%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, ARAY is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check MGRM's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, PMI has a market cap of 235.6M. Regarding current trading prices, ARAY is priced at $0.38, while PMI trades at $0.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas PMI's P/E ratio is -0.20. In terms of profitability, ARAY's ROE is -0.77%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ARAY is more volatile compared to PMI. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check PMI's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ARAY is priced at $0.38, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ARAY's ROE is -0.77%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ARAY is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check NVRO's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ARAY is priced at $0.38, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas EYES's P/E ratio is N/A. In terms of profitability, ARAY's ROE is -0.77%, compared to EYES's ROE of -2.64%. Regarding short-term risk, ARAY is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check EYES's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, PROF has a market cap of 206.7M. Regarding current trading prices, ARAY is priced at $0.38, while PROF trades at $6.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas PROF's P/E ratio is -5.51. In terms of profitability, ARAY's ROE is -0.77%, compared to PROF's ROE of -0.71%. Regarding short-term risk, ARAY is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check PROF's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, ANIK has a market cap of 198M. Regarding current trading prices, ARAY is priced at $0.38, while ANIK trades at $14.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas ANIK's P/E ratio is -18.84. In terms of profitability, ARAY's ROE is -0.77%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, ARAY is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check ANIK's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ARAY is priced at $0.38, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ARAY's ROE is -0.77%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, ARAY is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ARAY.Check BSGM's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, TMCI has a market cap of 180.3M. Regarding current trading prices, ARAY is priced at $0.38, while TMCI trades at $2.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas TMCI's P/E ratio is -2.90. In terms of profitability, ARAY's ROE is -0.77%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, ARAY is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check TMCI's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ARAY is priced at $0.38, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ARAY's ROE is -0.77%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ARAY is more volatile compared to MDGS. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check MDGS's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, INGN has a market cap of 173.3M. Regarding current trading prices, ARAY is priced at $0.38, while INGN trades at $6.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas INGN's P/E ratio is -7.03. In terms of profitability, ARAY's ROE is -0.77%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ARAY is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check INGN's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, APYX has a market cap of 172.9M. Regarding current trading prices, ARAY is priced at $0.38, while APYX trades at $4.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas APYX's P/E ratio is -18.77. In terms of profitability, ARAY's ROE is -0.77%, compared to APYX's ROE of -0.91%. Regarding short-term risk, ARAY is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check APYX's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ARAY is priced at $0.38, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ARAY's ROE is -0.77%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ARAY is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check QIPT's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, CVRX has a market cap of 162.1M. Regarding current trading prices, ARAY is priced at $0.38, while CVRX trades at $6.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas CVRX's P/E ratio is -3.04. In terms of profitability, ARAY's ROE is -0.77%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, ARAY is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check CVRX's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, EDAP has a market cap of 161.2M. Regarding current trading prices, ARAY is priced at $0.38, while EDAP trades at $4.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas EDAP's P/E ratio is -5.24. In terms of profitability, ARAY's ROE is -0.77%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, ARAY is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check EDAP's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, SNWV has a market cap of 143.5M. Regarding current trading prices, ARAY is priced at $0.38, while SNWV trades at $16.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas SNWV's P/E ratio is 17.39. In terms of profitability, ARAY's ROE is -0.77%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, ARAY is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check SNWV's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, QTI has a market cap of 136.5M. Regarding current trading prices, ARAY is priced at $0.38, while QTI trades at $5.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas QTI's P/E ratio is -4.79. In terms of profitability, ARAY's ROE is -0.77%, compared to QTI's ROE of -63.30%. Regarding short-term risk, ARAY is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check QTI's competition here

ARAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARAY stands at 36.5M. In comparison, HSDT has a market cap of 133.7M. Regarding current trading prices, ARAY is priced at $0.38, while HSDT trades at $2.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARAY currently has a P/E ratio of -0.81, whereas HSDT's P/E ratio is 0.01. In terms of profitability, ARAY's ROE is -0.77%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, ARAY is more volatile compared to HSDT. This indicates potentially higher risk in terms of short-term price fluctuations for ARAY.Check HSDT's competition here